ArticlePrenatal diagnosis2026
Moderate Diagnostic Yield of Exome Sequencing in Fetal Growth Restriction: Retrospective Insights.
Article in Prenatal diagnosis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo determine whether invasive genetic testing should be systematically proposed in cases of FGR.
methodsDescriptive retrospective study of 159 FGR cases (defined by an estimated fetal growth < 3rd percentile, regardless of Doppler findings) managed at the Toulouse Fetal Medicine Center (TFMC) during 2022-2023.
resultsMean gestational age at diagnosis was 23.7 weeks. Head circumference < 3rd percentile was observed in 35% of cases, hemodynamic signs in 57%, and oligohydramnios in 11%. Invasive testing was performed in 56% (n = 89) of cases, with a diagnostic yield in cases with hemodynamic signs of 19% for genetic syndromes (whether chromosomal or monogenic), which dropped to 11% (n = 8) in isolated FGR. Postnatally, 50% (n = 67) of cases were attributed to placental causes, 31% (n = 41) to genetic disorders (of which 41% had a negative prenatal genetic workup), while 13% remained unexplained. Placental causes were most often due to chronic maternal vascular malperfusion (72%).
conclusionFindings support the systematic offer of exome sequencing in second-trimester FGR, regardless of whether it is isolated, associated with head circumference < 3rd percentile, or with abnormal hemodynamic profiles.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.